Bio-Techne‘s patent involves systems and methods for analyzing gene delivery particles in samples to determine their quality and state. By establishing relationships between nucleic acid content and particle states, the technology can predict the proportion of particles in different states in test samples. GlobalData’s report on Bio-Techne gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Bio-Techne Corp - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bio-Techne, Peptide pharmacophores was a key innovation area identified from patents. Bio-Techne's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Method for analyzing gene delivery particles in samples

Source: United States Patent and Trademark Office (USPTO). Credit: Bio-Techne Corp

A recently granted patent (Publication Number: US11827946B2) outlines a method for analyzing viral vectors in a test sample. The method involves receiving two test signals associated with the sample, one linked to nucleic acid (NA) in a subset of viral vectors and the other to protein in another subset. By identifying specific features in these signals and comparing them to standard values obtained from known samples, the proportion of viral vectors in a full state can be determined. This innovative approach allows for a detailed analysis of the viral vectors present in the sample, providing valuable insights into their composition and state.

Furthermore, the method includes transmitting the determined proportion to an output device, enabling easy visualization of the results. By utilizing electrophoretic separation techniques and miniaturized fluidic paths, the method ensures precise separation and analysis of the viral vectors based on their properties. The patent also details the calculation of NA and protein quantities in the sample, as well as the use of standard curves to establish relationships between these quantities and the proportion of viral vectors in a full state. Overall, this patented method offers a comprehensive and efficient way to assess viral vector composition and state, with potential applications in various fields such as biotechnology and pharmaceuticals.

To know more about GlobalData’s detailed insights on Bio-Techne, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.